Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Identification of Fucosylated SERPINA1 as a Novel Plasma Marker for Pancreatic Cancer Using Lectin Affinity Capture Coupled with iTRAQ-Based Quantitative Glycoproteomics.

Tytuł:
Identification of Fucosylated SERPINA1 as a Novel Plasma Marker for Pancreatic Cancer Using Lectin Affinity Capture Coupled with iTRAQ-Based Quantitative Glycoproteomics.
Autorzy:
Wu CC; Molecular Medicine Research Center, Chang Gung University, Taoyuan 33302, Taiwan.
Lu YT; Molecular Medicine Research Center, Chang Gung University, Taoyuan 33302, Taiwan.
Yeh TS; Department of General Surgery, Chang Gung Memorial Hospital, Linkou 33305, Taiwan.; College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
Chan YH; Department of General Surgery, Chang Gung Memorial Hospital, Linkou 33305, Taiwan.
Dash S; Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
Yu JS; Molecular Medicine Research Center, Chang Gung University, Taoyuan 33302, Taiwan.; Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.; Liver Research Center, Chang Gung Memorial Hospital, Linkou 33305, Taiwan.; Research Center for Food and Cosmetic Safety, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 33302, Taiwan.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Jun 04; Vol. 22 (11). Date of Electronic Publication: 2021 Jun 04.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Biomarkers, Tumor/*blood
Fucose/*chemistry
Glycoproteins/*blood
Lectins/*chemistry
Pancreatic Neoplasms/*diagnosis
Proteome/*metabolism
alpha 1-Antitrypsin/*blood
Case-Control Studies ; Chromatography, Affinity ; Female ; Fucose/metabolism ; Humans ; Lectins/metabolism ; Male ; Mass Spectrometry ; Middle Aged ; Pancreatic Neoplasms/blood ; Proteome/analysis ; Survival Rate ; alpha 1-Antitrypsin/chemistry
References:
J Proteome Res. 2012 Sep 7;11(9):4541-52. (PMID: 22827608)
Genome Biol. 2006;7(8):R73. (PMID: 16901351)
Electrophoresis. 2018 Sep;39(18):2351-2361. (PMID: 29405331)
Anal Chem. 1999 Apr 1;71(7):1431-40. (PMID: 10204042)
Clin Chem. 2018 Aug;64(8):1230-1238. (PMID: 29875214)
Can J Gastroenterol Hepatol. 2018 Aug 14;2018:5389820. (PMID: 30186820)
Ann Transl Med. 2015 Jun;3(10):130. (PMID: 26207223)
J Proteome Res. 2014 Apr 4;13(4):2197-204. (PMID: 24575722)
Glycobiology. 2015 Mar;25(3):331-40. (PMID: 25347993)
J Chromatogr B Biomed Sci Appl. 2001 Mar 10;752(2):293-306. (PMID: 11270868)
Int J Cancer. 2006 Jun 1;118(11):2803-8. (PMID: 16385567)
J Clin Oncol. 2006 Nov 20;24(33):5313-27. (PMID: 17060676)
N Engl J Med. 2014 Sep 11;371(11):1039-49. (PMID: 25207767)
BMC Cancer. 2011 Dec 07;11:508. (PMID: 22152070)
Glycobiology. 2011 Feb;21(2):195-205. (PMID: 20861084)
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):405-11. (PMID: 20086110)
World J Oncol. 2019 Feb;10(1):10-27. (PMID: 30834048)
BMC Cancer. 2018 Apr 11;18(1):406. (PMID: 29642865)
Curr Opin Pharmacol. 2012 Jun;12(3):309-14. (PMID: 22365503)
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Dec 25;782(1-2):405-18. (PMID: 12458022)
Sci Rep. 2021 May 5;11(1):9583. (PMID: 33953300)
Proteomics Clin Appl. 2013 Oct;7(9-10):690-700. (PMID: 23857719)
Nat Protoc. 2006;1(6):3019-27. (PMID: 17406563)
Front Cell Dev Biol. 2020 Sep 03;8:550543. (PMID: 33015055)
Clin Chem Lab Med. 2010 Apr;48(4):505-12. (PMID: 20128732)
PLoS One. 2017 Mar 15;12(3):e0173897. (PMID: 28296934)
Oncotarget. 2016 Jun 7;7(23):35478-89. (PMID: 27007155)
BMJ. 2012 May 16;344:e2476. (PMID: 22592847)
Br J Surg. 1995 Jan;82(1):111-5. (PMID: 7881926)
Clin Chim Acta. 2001 Nov;313(1-2):15-9. (PMID: 11694234)
Mol Cell Proteomics. 2010 Sep;9(9):1819-28. (PMID: 20811073)
Digestion. 1985;31(1):37-40. (PMID: 3872237)
Oncotarget. 2018 Jan 4;9(15):12079-12100. (PMID: 29552294)
BMC Biochem. 2011 Mar 24;12:13. (PMID: 21435201)
Nat Methods. 2007 May;4(5):437-44. (PMID: 17417647)
Neuro Endocrinol Lett. 2010;31(1):113-6. (PMID: 20150872)
FEBS J. 2010 Jan;277(1):95-105. (PMID: 19919546)
Anal Bioanal Chem. 2016 Nov;408(27):7761-7774. (PMID: 27565792)
World J Gastroenterol. 2015 Apr 7;21(13):3876-87. (PMID: 25852272)
J Immunol Methods. 1991 Nov 5;144(1):77-86. (PMID: 1660058)
J Proteome Res. 2007 May;6(5):1864-74. (PMID: 17428079)
Anal Chem. 2011 Nov 15;83(22):8509-16. (PMID: 21975078)
Anal Chem. 2009 Jan 1;81(1):146-59. (PMID: 19061407)
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450. (PMID: 30395289)
J Proteome Res. 2013 Jul 5;12(7):3342-52. (PMID: 23731285)
Nat Biotechnol. 2003 Jun;21(6):667-72. (PMID: 12754521)
J Clin Invest. 2021 Jun 1;131(11):. (PMID: 33878034)
J Korean Med Sci. 1991 Sep;6(3):206-13. (PMID: 1663767)
J Proteome Res. 2011 May 6;10(5):2602-11. (PMID: 21417406)
BMC Cancer. 2014 May 21;14:355. (PMID: 24886427)
J Proteome Res. 2010 Feb 5;9(2):798-805. (PMID: 19961239)
J Proteome Res. 2014 Apr 4;13(4):1873-84. (PMID: 24571389)
J Food Drug Anal. 2019 Apr;27(2):483-493. (PMID: 30987719)
CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
Thorax. 2004 Mar;59(3):259-64. (PMID: 14985567)
Chem Rev. 2002 Dec;102(12):4751-804. (PMID: 12475206)
Grant Information:
MOST 109-2320-B-182-009-MY3 Ministry of Science and Technology, Taiwan; CLRPD1J0012 Chang Gung Memorial Hospital, Taiwan; CMRPD1H0253 Chang Gung Memorial Hospital, Taiwan
Contributed Indexing:
Keywords: AAL; fucosylated SERPINA1; glycobiomarker; iTRAQ-based quantitative proteome; pancreatic cancer; plasma; reverse lectin-based ELISA
Substance Nomenclature:
0 (Biomarkers, Tumor)
0 (Glycoproteins)
0 (Lectins)
0 (Proteome)
0 (SERPINA1 protein, human)
0 (alpha 1-Antitrypsin)
0 (lectin, Aleuria aurantia)
28RYY2IV3F (Fucose)
Entry Date(s):
Date Created: 20210702 Date Completed: 20210726 Latest Revision: 20210726
Update Code:
20240105
PubMed Central ID:
PMC8200073
DOI:
10.3390/ijms22116079
PMID:
34199928
Czasopismo naukowe
Pancreatic cancer (PC) is an aggressive cancer with a high mortality rate, necessitating the development of effective diagnostic, prognostic and predictive biomarkers for disease management. Aberrantly fucosylated proteins in PC are considered a valuable resource of clinically useful biomarkers. The main objective of the present study was to identify novel plasma glycobiomarkers of PC using the iTRAQ quantitative proteomics approach coupled with Aleuria aurantia lectin (AAL)-based glycopeptide enrichment and isotope-coded glycosylation site-specific tagging, with a view to analyzing the glycoproteome profiles of plasma samples from patients with non-metastatic and metastatic PC and gallstones (GS). As a result, 22 glycopeptides with significantly elevated levels in plasma samples of PC were identified. Fucosylated SERPINA1 (fuco-SERPINA1) was selected for further validation in 121 plasma samples (50 GS and 71 PC) using an AAL-based reverse lectin ELISA technique developed in-house. Our analyses revealed significantly higher plasma levels of fuco-SERPINA1 in PC than GS subjects (310.7 ng/mL v.s. 153.6 ng/mL, p = 0.0114). Elevated fuco-SERPINA1 levels were associated with higher TNM stage ( p = 0.024) and poorer prognosis for overall survival (log-rank test, p = 0.0083). The increased plasma fuco-SERPINA1 levels support the utility of this protein as a novel prognosticator for PC.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies